Modeling the role of microRNA-449a in the regulation of the G2/M cell cycle checkpoint in prostate LNCaP cells under ionizing radiation *S1 file*

Shantanu Gupta^{1,+}, Daner A. Silveira^{1,+} and José C. M. Mombach^{1,+,*}

¹Departmento de Física, Universidade Federal de Santa Maria, Santa Maria, RS, 97105-900, Brazil

> *Corresponding author (e-mail: jcmombach@ufsm.br) +These authors contributed equally to this work

Bibliographical references of the interactions among the molecules of the model

 $IR \rightarrow miR-449a [1, 2]$ $IR \rightarrow ATR [3]$ $IR \rightarrow ATM [3]$ $p21 \rightarrow G2/M$ -Arrest [4] p53-Main \rightarrow p53-Arrest [5] p53-Main \rightarrow p53-Killer [6] p53-Main \rightarrow Mdm2 [7] p53-Main \rightarrow G2/M-Arrest [8] $14-3-3s \rightarrow G2/M-Arrest$ [9] $Cdc25ABC \rightarrow E2F1$ [10] $Myc \rightarrow Cdc25ABC$ [11] Myc \rightarrow E2F1 [12] $E2F1 \rightarrow Myc [12]$ $E2F1 \rightarrow Sirt-1$ [13] $E2F1 \rightarrow p53$ -Main [14] $E2F1 \rightarrow Proliferation [15]$ ATM \rightarrow E2F1 [16] $ATM \rightarrow p53 [17]$ $ATR \rightarrow E2F1$ [16] ATR \rightarrow p53 [17] $E2F1 \rightarrow ATM$ [18] $Cdc25ABC \rightarrow Cdc2-CycB$ [19] $Cdc2-CvcB \rightarrow Proliferation [20]$ p53-Killer → 14-3-3 [21] p53-Killer \rightarrow p21 [22, 8] p53-Killer \rightarrow G2/M-Apoptosis [23] p53-Arrest → 14-3-3 [21] p53-Arrest \rightarrow p21 [22, 8] p53-Arrest \rightarrow Wip1 [24] p53-Arrest \rightarrow p53INP1 [25] p53INP1 ⊣ p53-Arrest [25] p21 ⊣ Cdc2-CycB [26] p53-Main ⊢ Proliferation [27] p53-Arrest ⊣ p53-killer [28] p53-Killer ⊣ p53-Arrest [28] $MDM2 \dashv RB$ [29] MDM2 - P53-Main [7] MDM2 ⊢ [30] Wip1 ⊣ p53-Killer [31] Wip1 ⊣ mdm2 [31] Wip1 ⊣ ATM [32] ATM - Cdc25ABC [33] ATM ⊣ Mdm2 [34]

```
ATR \dashv Mdm2 [35]
ATR ⊣ Cdc25ABC [33]
Sirt-1 \dashv p53-Arrest [36]
Sirt-1 ⊣ p53-Killer [36]
Sirt-1 ⊢ E2F1 [13]
Sirt-1 ⊢ RB [37]
miR-449a ⊣ Myc [1, 2]
c-Myc ⊢ p21 [38]
miR-449a - Cdc25ABC [39]
Cdc25ABC \dashv Rb [40]
miR-449a - Sirt-1 [41]
sirt-1 ⊢ P53 [42]
14-3-3 ⊣ Cdc2-CycB [43]
Rb \dashv E2F1 [44]
Rb \dashv c-Myc [45]
Rb \dashv mdm2 [46]
miR-449a - E2F1 [39]
```

References

- [1] Aihong Mao, Qiuyue Zhao, Xin Zhou, Chao Sun, Jing Si, Rong Zhou, Lu Gan, and Hong Zhang. MicroRNA-449a enhances radiosensitivity by downregulation of c-Myc in prostate cancer cells. *Scientific reports*, 6:27346, 2016.
- [2] Aihong Mao, Yang Liu, Yali Wang, Qiuyue Zhao, Xin Zhou, Chao Sun, Cuixia Di, Jing Si, Lu Gan, and Hong Zhang. MiR-449a enhances radiosensitivity through modulating pRb/E2F1 in prostate cancer cells. *Tumor Biology*, 37(4):4831– 4840, 2016.
- [3] Jeremy S Myers and David Cortez. Rapid activation of ATR by ionizing radiation requires ATM and Mre11. *Journal of Biological Chemistry*, 281(14):9346–9350, 2006.
- [4] Alexander B Niculescu, Xinbin Chen, Monique Smeets, Ludger Hengst, Carol Prives, and Steven I Reed. Effects of p21Cip1/Waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. *Molecular and cellular biology*, 18 (1):629–643, 1998.
- [5] Natalia S Pellegata, Ronald J Antoniono, J Leslie Redpath, and Eric J Stanbridge. DNA damage and p53-mediated cell cycle arrest: a reevaluation. *Proceedings* of the National Academy of Sciences, 93(26):15209–15214, 1996.
- [6] E Christine Pietsch, Stephen M Sykes, Steven B McMahon, and Maureen E Murphy. The p53 family and programmed cell death. *Oncogene*, 27(50):6507–6521, 2008.

- [7] Ute M Moll and Oleksi Petrenko. The MDM2-p53 interaction. *Molecular cancer research*, 1(14):1001–1008, 2003.
- [8] William R Taylor and George R Stark. Regulation of the G2/M transition by p53. Oncogene, 20(15):1803, 2001.
- [9] Heiko Hermeking, Christoph Lengauer, Kornelia Polyak, Tong-Chuan He, Lin Zhang, Sam Thiagalingam, Kenneth W Kinzler, and Bert Vogelstein. 14-3-3 σ is a p53-regulated inhibitor of G2/M progression. *Molecular cell*, 1(1):3–11, 1997.
- [10] Tao Shen and Shile Huang. The role of Cdc25A in the regulation of cell proliferation and apoptosis. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*, 12(6):631–639, 2012.
- [11] S Aref, M Fouda, E El-Dosoky, A Menessy, M Mabed, M Saleeb, and K Zalata. C-Myc oncogene and Cdc25A cell activating phosphatase expression in nonhodgkin's lymphoma. *Hematology*, 8(3):183–190, 2003.
- [12] JY Leung, GL Ehmann, PH Giangrande, and JR Nevins. A role for Myc in facilitating transcription activation by E2F1. *Oncogene*, 27(30):4172–4179, 2008.
- [13] Chuangui Wang, Lihong Chen, Xinghua Hou, Zhenyu Li, Neha Kabra, Yihong Ma, Shino Nemoto, Toren Finkel, Wei Gu, W Douglas Cress, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. *Nature cell biology*, 8(9):1025–1031, 2006.
- [14] Jung-Kuang Hsieh, Damian Yap, Daniel J O'Connor, Valentina Fogal, Lynn Fallis, Florence Chan, Shan Zhong, and Xin Lu. Novel function of the cyclin a binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. *Molecular and cellular biology*, 22(1):78–93, 2002.
- [15] Sanghoon Lee, Jung Nyeo Chun, Su-Hwa Kim, Insuk So, and Ju-Hong Jeon. Icilin inhibits E2F1-mediated cell cycle regulatory programs in prostate cancer. *Biochemical and biophysical research communications*, 441(4):1005–1010, 2013.
- [16] Weei-Chin Lin, Fang-Tsyr Lin, and Joseph R Nevins. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. *Genes & development*, 15(14):1833–1844, 2001.
- [17] DNA damage sensing by the ATM] and ATR kinases, author=Maréchal, Alexandre and Zou, Lee, journal=Cold Spring Harbor perspectives in biology, volume=5, number=9, pages=a012716, year=2013, publisher=Cold Spring Harbor Lab.
- [18] Eli Berkovich and Doron Ginsberg. ATM is a target for positive regulation by E2F-1. *Oncogene*, 22(2):161–167, 2003.

- [19] Oleg Timofeev, Onur Cizmecioglu, Florian Settele, Tore Kempf, and Ingrid Hoffmann. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. *Journal of Biological Chemistry*, 285(22):16978–16990, 2010.
- [20] Hisanori Kawamoto, Hirotaka Koizumi, and Toshiyuki Uchikoshi. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. *The American journal of pathology*, 150(1):15, 1997.
- [21] Heng-Yin Yang, Yu-Ye Wen, Chih-Hsin Chen, Guillermina Lozano, and Mong-Hong Lee. 14-3-3 σ positively regulates p53 and suppresses tumor growth. *Molecular and cellular biology*, 23(20):7096–7107, 2003.
- [22] Guangan He, Zahid H Siddik, Zaifeng Huang, Ruoning Wang, John Koomen, Ryuji Kobayashi, Abdul R Khokhar, and Jian Kuang. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. *Oncogene*, 24 (18):2929–2943, 2005.
- [23] Susan Haupt, Michael Berger, Zehavit Goldberg, and Ygal Haupt. Apoptosisthe p53 network. *Journal of cell science*, 116(20):4077–4085, 2003.
- [24] Mutsuhiro Takekawa, Masaaki Adachi, Atsuko Nakahata, Ichiro Nakayama, Fumio Itoh, Hiroyuki Tsukuda, Yoichi Taya, and Kohzoh Imai. p53-inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. *The EMBO journal*, 19(23):6517–6526, 2000.
- [25] Shu Okamura, Hirofumi Arakawa, Tomoaki Tanaka, Hiroshi Nakanishi, Ching Ching Ng, Yoichi Taya, Morito Monden, and Yusuke Nakamura. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. *Molecular cell*, 8(1):85–94, 2001.
- [26] Ludger Hengst, Ulrich Göpfert, Hilal A Lashuel, and Steven I Reed. Complete inhibition of Cdk/cyclin by one molecule of p21Cip1. *Genes & development*, 12 (24):3882–3888, 1998.
- [27] Joongkyu Park, Yohan Oh, Lang Yoo, Min-Su Jung, Woo-Joo Song, Sang-Hun Lee, Hyemyung Seo, and Kwang Chul Chung. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. *Journal of Biological Chemistry*, 285(41):31895–31906, 2010.
- [28] Steven E Artandi and Laura D Attardi. Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. *Biochemical and biophysical research communications*, 331(3):881–890, 2005.
- [29] Zhi-Xlong Xiao, Jiandong Chen, Arnold J Levine, Nazanlne Modjtahedi, Jun Xing, William R Sellers, and David M Livingston. Interaction between the retinoblastoma protein and the oncoprotein MDM2. *Nature*, 375(6533):694, 1995.

- [30] Luciana E Giono and James J Manfredi. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest. *Molecular and cellular biology*, 27(11):4166–4178, 2007.
- [31] Xiongbin Lu, Ou Ma, Thuy-Ai Nguyen, Stephen N Jones, Moshe Oren, and Lawrence A Donehower. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. *Cancer cell*, 12(4):342–354, 2007.
- [32] Sathyavageeswaran Shreeram, Oleg N Demidov, Weng Kee Hee, Hiroshi Yamaguchi, Nobuyuki Onishi, Calvina Kek, Oleg N Timofeev, Crissy Dudgeon, Albert J Fornace, Carl W Anderson, et al. Wip1 phosphatase modulates ATMdependent signaling pathways. *Molecular cell*, 23(5):757–764, 2006.
- [33] Maria Thanasoula, Jose Miguel Escandell, Natsuko Suwaki, and Madalena Tarsounas. ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres. *The EMBO journal*, 31(16):3398–3410, 2012.
- [34] Ruth Maya, Moshe Balass, Seong-Tae Kim, Dganit Shkedy, Juan-Fernando Martinez Leal, Ohad Shifman, Miri Moas, Thomas Buschmann, Ze'ev Ronai, Yosef Shiloh, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. *Genes & development*, 15(9):1067–1077, 2001.
- [35] Tomomi Shinozaki, Ayumi Nota, Yoichi Taya, and Koji Okamoto. Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export. *Oncogene*, 22(55):8870–8880, 2003.
- [36] Jingjie Yi and Jianyuan Luo. SIRT1 and p53, effect on cancer, senescence and beyond. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics*, 1804(8): 1684–1689, 2010.
- [37] Beata Jablonska, Marcin Gierdalski, Li-Jin Chew, Teresa Hawley, Mackenzie Catron, Arturo Lichauco, Juan Cabrera-Luque, Tracy Yuen, David Rowitch, and Vittorio Gallo. Sirt1 regulates glial progenitor proliferation and regeneration in white matter after neonatal brain injury. *Nature communications*, 7:13866, 2016.
- [38] Andrei L Gartel, Xin Ye, Eugene Goufman, Pavel Shianov, Nissim Hay, Feridoon Najmabadi, and Angela L Tyner. Myc represses the p21 (WAF1/CIP1) promoter and interacts with Sp1/Sp3. *Proceedings of the National Academy of Sciences*, 98(8):4510–4515, 2001.
- [39] Xiaojing Yang, Min Feng, Xia Jiang, Zhenlong Wu, Zhimei Li, Meiyee Aau, and Qiang Yu. MiR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. *Genes & development*, 23(20):2388–2393, 2009.
- [40] Maddalena Donzelli and Giulio F Draetta. Regulating mammalian checkpoints through Cdc25 inactivation. *EMBO reports*, 4(7):671–677, 2003.

- [41] Parameet Kumar, Shashwat Sharad, Gyorgy Petrovics, Ahmed Mohamed, Albert Dobi, Taduru L Sreenath, Shiv Srivastava, and Roopa Biswas. Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1. *Oncotarget*, 7(16):22791, 2016.
- [42] Ling Li, Lisheng Wang, Liang Li, Zhiqiang Wang, Yinwei Ho, Tinisha McDonald, Tessa L Holyoake, WenYong Chen, and Ravi Bhatia. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. *Cancer cell*, 21(2):266–281, 2012.
- [43] Paulette Mhawech. 14-3-3 proteins—an update. Cell research, 15(4):228–236, 2005.
- [44] SW Hiebert, SP Chellappan, JM Horowitz, and JR Nevins. The interaction of rb with E2F coincides with an inhibition of the transcriptional activity of E2F. *Genes & development*, 6(2):177–185, 1992.
- [45] Roderick L Beijersbergen, E Marielle Hijmans, Liang Zhu, and Rene Bernards. Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Myc-mediated transactivation. *The EMBO journal*, 13(17):4080, 1994.
- [46] Damian BS Yap, Jung-Kuang Hsieh, Florence SG Chan, and Xin Lu. mdm2: a bridge over the two tumour suppressors, p53 and Rb. *Oncogene*, 18(53):7681, 1999.